Welcome to Bayside Health | Alfred. More information about Bayside Health can be found at baysidehealth.org.au

Contact About Find a doctor Careers The Alfred Foundation For staff

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Clear filter

636 clinical trials found

Clinical trials

TRICS-IV

TRICS IV: Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery. An international, multi-centre, randomized controlled trial to assess (NCT04754022)

Currently recruiting

TRIGS

Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial (NCT04192435)

Currently recruiting

TRIlogy-4

A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody (NCT07258511)

JNJ-79635322 (BCMAxGPRC5DxCD3) is a novel immunoglobulin G1 trispecific antibody targeting the T-cell receptor (CD3 portion) with 1 binding arm and 2 plasma cell target antigen binding domains (BCMA and GPRC5D). The primary objective is to compare the efficacy of JNJ-79635322 with an anti-BCMAxCD3 bispecific antibody (Teclistamab), based on dual primary endpoints of ORR and PFS, in participants with RRMMwho have received at least 3 prior lines of therapy including a PI, an IMiD, and an anti-CD38 antibody.

Currently recruiting

TRITON

A Feasibility Trial of Tranexamic Acid for Necrotising Soft-Tissue Infections (ACTRN12621001423808)

Currently recruiting

TRIUMPH

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index =27 kg/m^2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease. (NCT06383390)

No longer recruiting

TRUST

Toxicity Reduction with Urethra Sparing radiation Therapy for prostate cancer (ACTRN12625000487415)

Currently recruiting

UAE-E

A prospective pilot study of the safety and effectiveness of Uterine Artery Embolisation for the treatment of Endometriosis (ACTRN12622001301752)

Currently recruiting

UCB STACCATO ALPRAZOLAM-DB

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures (NCT05077904)

Currently recruiting

UCB STACCATO ALPRAZOLAM-OLE

An open-label, multicenter, outpatient extension study to evaluate the safety and tolerability of Staccato Alprazolam in study participants 12 years of age and older with stereotypical prolonged seizures (NCT05076617)

Currently recruiting

V940-001

A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (NCT05933577)

No longer recruiting

VANTAGE

VANTAGE Clinical Trial: (Evaluation of TAVI using the NAVITOR valve in a Global Investigation) (NCT04788888)

No longer recruiting

VBE00001

A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age (NCT06316297)

The aim of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 administrations of the Acne mRNA vaccine candidate at up to 3 dose levels (45 µg, 120 µg and 225 µg total mRNA) in adults aged 18 to 45 years with moderate to severe acne. This is a phase I/II trial, in which about 260 people will take part in this study worldwide. 36/260 will be randomized in Sentinel cohort A, 200 participants in the main cohort A and 24 participants in Sentinel cohort B.

Currently recruiting

VECTORS

An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients with Moderately to Severely Active Crohn’s Disease [VECTORS] (NCT06257706)

Currently recruiting

VELOCITY-HNSCC GS-US-699-7184

A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma VELOCITY-HNSCC Substudy-01: A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status (NCT06727565)

Currently recruiting

Velora Discover - HMB-002-101_SCR

A Prospective, Screening Study of Bleeding and Treatment in Participants with Von Willebrand Disease

This is a non-interventional observational study in participants with confirmed Type 1 VWD according to diagnostic guidelines. The study includes screening, a baseline evaluation, and an approximately 4-month observation period which will include every other week telemedicine check-ins (to monitor bleed diary entries and bleeding event treatments.?

Currently recruiting

VENTURA-LT

An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) (NCT05518149)

Currently recruiting

VENTYX

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants with Moderately to Severely Active Crohn's Disease (NCT05688852)

Currently recruiting

VERTEX

A Phase 1/2, Randomized, Double-blind, Placebo controlled Single- and Multiple dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX 670 in Adult Subjects with Myotonic Dystrophy Type 1 (NCT06185764)

Currently recruiting

VERTEX

A Phase 1/2, Randomized, Double-blind, Placebo controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects with Myotonic Dystrophy Type 1 (NCT06185764)